Pfizer Inc.: Drug Recall
Recall #D-0097-2023 · 12/29/2022
Class II: Risk
Recall Details
- Recall Number
- D-0097-2023
- Classification
- Class II
- Product Type
- Drug
- Recalling Firm
- Pfizer Inc.
- Status
- Completed
- Date Initiated
- 12/29/2022
- Location
- New York, NY, United States
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 62,088 bags
Reason for Recall
Lack of assurance of sterility: Bags have the potential to leak.
Product Description
Heparin Sodium 2,000, USP Units, per 1,000 mL (2 USP Units/mL) in 0.9% Sodium Chloride Injection, 1,000 mL bags, a) Case (NDC 0409-7620-59), b) Single Unit (NDC 0409-7620-49), Rx only, Distributed By Hospira, Inc., Lake Forest, IL 60045 USA,
Distribution Pattern
Nationwide in the USA.
Other Recalls by Pfizer Inc.
- Class II: Risk 08/04/2025
- Class II: Risk 08/04/2025
- Class II: Risk 07/10/2025
- Class II: Risk 07/10/2025
- Class II: Risk 05/28/2025
Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.